RT Journal Article
T1 Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review.
A1 Gomez-Garcia, Francisco
A1 Gomez-Arias, Pedro Jesus
A1 Hernandez, Jorge
A1 Montilla, Ana Maria
A1 Gay-Mimbrera, Jesus
A1 Aguilar-Luque, Macarena
A1 Viguera-Guerra, Isabel
A1 Velez Garcia-Nieto, Antonio
A1 Isla-Tejera, Beatriz
A1 Ruano, Juan
K1 JAK/STAT pathway
K1 PRISMA
K1 Immune-mediated inflammatory skin diseases
K1 Protocol
K1 Scoping review
AB The Janus kinase and Signal Transducer and Activator of Transcription protein (JAK/STAT) pathway is known to be involved in inflammatory and neoplastic skin diseases, like psoriasis, atopic dermatitis, alopecia areata, vitiligo and melanoma. Improved knowledge of the components of this pathway has allowed the development of drugs, which act by inhibiting the pathway, blocking specific components. This offers new therapeutic opportunities. Although evidence on the use of JAK/STAT blockades in dermatological diseases is growing, none have been approved for use in treating skin diseases. The aim of this study is to develop an a priori protocol to broadly review the available evidence on the use of drugs targeting the JAK/STAT pathway in the treatment of dermatological diseases. For the conduction of the scoping review protocol, we will employ an established scoping review methodology described in the Joanna Briggs Institute manual. This methodology outlines a five-stage approach: (1) identify the research question; (2) identify relevant studies; (3) select studies; (4) chart the data and (5) collate, summarise and report the results, with an optional consultation exercise. Finally, we will use the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews to present the results. Since this is a review of the literature, ethics approval is not indicated. We will disseminate the findings from this study in publications in peer-reviewed journals as well as presentations at relevant national and international conferences.
PB BMJ Group
YR 2019
FD 2019-04-15
LK http://hdl.handle.net/10668/14010
UL http://hdl.handle.net/10668/14010
LA en
NO Gómez-García F, Gómez-Arias PJ, Hernandez J, Montilla AM, Gay-Mimbrera J, Aguilar-Luque M, et al. Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review. BMJ Open. 2019 May 22;9(5):e028303
DS RISalud
RD Apr 8, 2025